Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

76.31 +0.06 (+0.08%)
Streaming Delayed Price Updated: 12:58 PM EDT, Jun 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,553,415
Open 76.00
Bid (Size) 76.30 (4)
Ask (Size) 76.31 (1)
Prev. Close 76.25
Today's Range 75.44 - 77.08
52wk Range 73.31 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 4.25%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
The deal is being discussed ahead of key data from MoonLake in patients with a skin disease. 
Via Investor's Business Daily
Merck's Dealmaking Intensifies With MoonLake Bid As Keytruda Patent Cliff Nears: Report
Merck reportedly offered over $3 billion for MoonLake Immunotherapeutics, targeting its late-stage inflammatory drug as it faces revenue pressure from Keytruda's looming patent cliff. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-23.1%
-23.1%
1 Month
-8.3%
-8.3%
3 Month
-16.4%
-16.4%
6 Month
-24.6%
-24.6%
1 Year
-39.5%
-39.5%

More News

Read More
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
Via Benzinga
How Do Investors Really Feel About Merck & Co?
Via Benzinga
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
From HKTDC
Via ACN Newswire
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
Via Investor's Business Daily
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
From Merck & Co., Inc.
Via Business Wire
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
Via StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
Via Stocktwits
Exposures Product Safety
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
Via Benzinga
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
From Daiichi Sankyo
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck Announces Third-Quarter 2025 Dividend
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
Via Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
Via The Motley Fool
Topics Earnings Economy World Trade
Exposures Economy Financial Tariff
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
Via Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
Via StockStory
Topics Stocks
Exposures US Equities
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
Via MarketBeat
Topics Government
Exposures COVID-19 Political
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Merck & Co., Inc.
Via Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
Exposures Economy Legal Product Safety
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
Via Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
Via Chartmill

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 76.31
When was Merck & Co last traded?
The last trade of Merck & Co was at 06/03/25 12:58 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 193.17B
How many shares of Merck & Co are outstanding?
Merck & Co has 193B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.